Details of the Drug

General Information of Drug (ID: DM3P6V7)

• Drug Name: Furazolidone
• Synonyms: Bifuron; Corizium; Coryzium; Diafuron; Enterotoxon; Furall; Furaxon; Furaxone; Furazol; Furazolidine; Furazolidon; Furazolidona; Furazolidonum; Furazolum; Furazon; Furidon; Furovag; Furox; Furoxal; Furoxane; Furoxon; Furoxone; Furozolidine; Giardil; Giarlam; Medaron; Neftin; Nicolen; Nifulidone; Nifuran; Nifurazolidone; Nifurazolidonum; Nitrofurazolidone; Nitrofurazolidonum; Nitrofuroxon; Optazol; Ortazol; Puradin; Roptazol; Sclaventerol; Tikofuran; Topazone; Trichofuron; Tricofuron; Tricoron; Trifurox; Viofuragyn; Fiurox aerosol powder; Furoxone Liquid; Furoxone Swine Mix; NF 180 custom mix ten; F-8900; Furazolidona [INN-Spanish]; Furazolidone [INN:BAN]; Furazolidonum [INN-Latin]; Furox Aerosol Powder (Veterinary); Furoxone (TN); NF-180; Usaf ea-1; Dependal-M (TN); Furazolidone (USP/INN); N-(5-Nitro-2-furfurylidene)-3-amino-2-oxazolidone; N-(5-Nitro-2-furfurylidene)-3-aminooxazolidine-2-one; 3-(((5-Nitro-2-furanyl)methylene)amino)-2-oxazolidinone; 3-((5-Nitrofurfurylidene)amino)-2-oxazolidinone; 3-((5-Nitrofurfurylidene)amino)-2-oxazolidone; 3-((5-Nitrofurylidene)amino)-2-oxazolidone; 3-(5'-Nitrofurfuralamino)-2-oxazolidone; 3-(5-Nitrofurfurylideneamino)-2-oxazolidinone; 3-[(5-Nitrofurfurylidene)amino]-2-oxazolidinone; 3-[(5-Nitrofurfurylidene)amino]-2-oxazolidone; 3-[(5-Nitrofurylidene)amino]-2-oxazolidone; 3-[(E)-(5-nitrofuran-2-yl)methylideneamino]-1,3-oxazolidin-2-one; 3-[[(5-Nitro-2-furanyl)methylene]amino]-2-oxazolidinone; 3-{[(5-Nitro-2-furanyl)methylene]amino}-2-oxazolidinone; 3-{[(5-nitro-2-furyl)methylene]amino}-1,3-oxazolidin-2-one; 3-{[(E)-(5-nitrofuran-2-yl)methylidene]amino}-1,3-oxazolidin-2-one; 5-Nitro-N-(2-oxo-3-oxazolidinyl)-2-furanmethanimine

Indication

Disease Entry	ICD 11	Status	REF
Diarrhea	ME05.1	Approved	[1]

• Therapeutic Class: Antiinfective Agents
• Affected Organisms: Microbes (bacteria, parasites)
• ATC Code:
  G01AX06: Furazolidone
  G01AX: Other antiinfectives and antiseptics
  G01A: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS
  G01: GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS
  G: GENITO URINARY SYSTEM AND SEX HORMONES
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 225.16
  Logarithm of the Partition Coefficient (xlogp); -0.1
  Rotatable Bond Count (rotbonds); 2
  Hydrogen Bond Donor Count (hbonddonor); 0
  Hydrogen Bond Acceptor Count (hbondacc); 6
• ADMET Property:
  Half-life: The concentration or amount of drug in body reduced by one-half in 10 minutes [2]
  Metabolism: The drug is metabolized via the conjugation with glutathione []

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Decreased appetite	Not Available	ALPL	OTG7J4BP	[3]
Decreased appetite	Not Available	GPT	OTOXOA0Q	[3]

• Chemical Identifiers:
  Formula: C8H7N3O5
  IUPAC Name: 3-[(E)-(5-nitrofuran-2-yl)methylideneamino]-1,3-oxazolidin-2-one
  Canonical SMILES: C1COC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-]
  InChI: InChI=1S/C8H7N3O5/c12-8-10(3-4-15-8)9-5-6-1-2-7(16-6)11(13)14/h1-2,5H,3-4H2/b9-5+
  InChIKey: PLHJDBGFXBMTGZ-WEVVVXLNSA-N
• Cross-matching ID:
  PubChem CID: 5323714
  ChEBI ID: CHEBI:5195
  CAS Number: 67-45-8
  UNII: 5J9CPU3RE0
  DrugBank ID: DB00614
  TTD ID: D03CUF

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial Deoxyribonucleic acid (Bact DNA)	TTS1W4A	NOUNIPROTAC	Modulator	[4]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Alanine aminotransferase 1 (GPT)	OTOXOA0Q	ALAT1_HUMAN	Drug Response	[3]
Alkaline phosphatase, tissue-nonspecific isozyme (ALPL)	OTG7J4BP	PPBT_HUMAN	Drug Response	[3]
Breast cancer type 1 susceptibility protein (BRCA1)	OT5BN6VH	BRCA1_HUMAN	Gene/Protein Processing	[5]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Gene/Protein Processing	[6]
Cyclin-dependent kinase 6 (CDK6)	OTR95N0X	CDK6_HUMAN	Gene/Protein Processing	[7]
Cyclin-dependent kinase inhibitor 1 (CDKN1A)	OTQWHCZE	CDN1A_HUMAN	Gene/Protein Processing	[6]
DNA damage-inducible transcript 3 protein (DDIT3)	OTI8YKKE	DDIT3_HUMAN	Gene/Protein Processing	[5]
Endoplasmic reticulum chaperone BiP (HSPA5)	OTFUIRAO	BIP_HUMAN	Gene/Protein Processing	[5]
G1/S-specific cyclin-D1 (CCND1)	OT8HPTKJ	CCND1_HUMAN	Gene/Protein Processing	[7]
G1/S-specific cyclin-D3 (CCND3)	OTNKPQ22	CCND3_HUMAN	Gene/Protein Processing	[7]

References

• [1] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 011270.
• [2] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [3] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [4] Interaction of furazolidone with DNA. Biochim Biophys Acta. 1975 Aug 21;402(2):161-5.
• [5] Involvement of the activation of Nrf2/HO-1, p38 MAPK signaling pathways and endoplasmic reticulum stress in furazolidone induced cytotoxicity and S phase arrest in human hepatocyte L02 cells: modulation of curcumin. Toxicol Mech Methods. 2017 Mar;27(3):165-172. doi: 10.1080/15376516.2016.1273424. Epub 2017 Jan 8.
• [6] P21(Waf1/Cip1) plays a critical role in furazolidone-induced apoptosis in HepG2 cells through influencing the caspase-3 activation and ROS generation. Food Chem Toxicol. 2016 Feb;88:1-12. doi: 10.1016/j.fct.2015.12.004. Epub 2015 Dec 11.
• [7] Involvement of the p38 MAPK signaling pathway in S-phase cell-cycle arrest induced by Furazolidone in human hepatoma G2 cells. J Appl Toxicol. 2013 Dec;33(12):1500-5. doi: 10.1002/jat.2829. Epub 2012 Oct 30.